Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Innocuité et efficacité à long terme de l'odevixibat chez les patients atteints du syndrome d'Alagille (ASSERT-EXT)

20 octobre 2026 mis à jour par: Albireo, an Ipsen Company

Une étude ouverte pour évaluer l'innocuité et l'efficacité à long terme de l'odevixibat (A4250) chez les patients atteints du syndrome d'Alagille (ASSERT-EXT)

The purpose of this study is to assess the long-term safety and effectiveness of odevixibat in participants with Alagille syndrome (ALGS).

The participants of this study will have ALGS a rare genetic disorder that can affect multiple organ systems of the body including the liver, heart, skeleton, eyes and kidneys. Common symptoms, which often develop during the first three months of life, include blockage of the flow of bile from the liver (cholestasis), yellowing of the skin and mucous membranes (jaundice), poor weight gain and growth and severe itching (pruritis).

The drug used for the study is odevixibat and was authorized for the treatment of cholestatic pruritus in infants with ALGS over 12 months of age by the United States Food and Drug Administration on 13 June 2023.

Aperçu de l'étude

Statut

Actif, ne recrute pas

Les conditions

Intervention / Traitement

Description détaillée

This Phase 3, open-label, multi-center extension study will have two groups of participants: Cohort 1 (participants who participated in Study A4250-012 [NCT04674761; ASSERT] and meet the entry criteria for this study) and Cohort 2 (infants under 12 months of age) with ALGS.

The study will consist of 2 or 3 periods:

  1. A 'Treatment period' of 72 weeks (cohort 1) or 12 weeks (cohort 2). Participants will visit the clinic every 4 to 12 weeks and will receive a dose of 120 μg/kg odevixibat daily.
  2. An 'Optional extension period' where participants who wish to continue receiving odevixibat after the 'treatment period' will have the opportunity to remain on treatment with visits every 16 weeks until the drug is commercially available. The optional extension is available provided continued use is supported by the risk-benefit profile, the participant has not been previously withdrawn or discontinued from the study, and the study is not terminated by the Sponsor.
  3. A 'Safety follow-up period' of 4 weeks (cohort 1) or 2 weeks (cohort 2). The Safety Follow-up Period will not occur for those who remain on treatment in the optional extension period.

Participants will need to complete an e-diary and questionnaires throughout the study (cohort 1 only). Participants will undergo blood samplings, urine collections (cohort 1 only), physical examinations, and clinical evaluations. They may continue some other medications, but the details need to be recorded.

Type d'étude

Interventionnel

Inscription (Réel)

62

Phase

  • Phase 3

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

      • Berlin, Allemagne, 13353
        • Charité - Universitätsmedizin Berlin
      • Hanover, Allemagne, 30625
        • Medizinische Hochschul
      • Tübingen, Allemagne, 72076
        • Universitatsklinik fur Kinder-und Jugendmedizin Tubingen
      • Brussels, Belgique, 1200
        • Cliniques Universitaires Saint-Luc Bruxelles
      • Bron, France, 69677
        • Hôpital Femme Mère Enfant de Lyon
      • Lille, France
        • Antenne pediatrique du CIC-Hopital Jeanne De Flandre
      • Paris, France, 75015
        • Hopital Necker Enfants Malades
      • Florence, Italie
        • AOU Meyer
      • Padova, Italie, 35128
        • Azienda Ospedale University
      • Rome, Italie, 00165
        • Ospedale Pediatrico Bambino Gesu
      • Kuala Lumpur, Malaisie, 59100
        • University of Malaya Medical Center
      • Groningen, Pays-Bas, 9713 GZ
        • Universitair Medisch Centrum Groningen
      • Utrecht, Pays-Bas
        • Wilhelmina Children's Hospital UMCU Utrecht
      • Warsaw, Pologne, 04-730
        • Instytut Pomnik-Centrum Zdrowia Dzieck
      • Birmingham, Royaume-Uni
        • Birmingham Women's and Children's NHS Foundation Trust
      • London, Royaume-Uni, SE5 9RS
        • King's College Hospital NHS Foundation Trust King's College Hospital Paediatric Research
      • Istanbul, Turquie (Türkiye)
        • Istanbul University Istanbul Medical Faculty Hospital
    • California
      • San Diego, California, États-Unis, 92123
        • Rady Children's Hospital
      • San Francisco, California, États-Unis, 94158
        • UCSF
    • Georgia
      • Atlanta, Georgia, États-Unis, 30329
        • Children's Healthcare of Atlanta
    • Indiana
      • Indianapolis, Indiana, États-Unis, 46202
        • Riley Hospital for Children at IU Health
    • Maryland
      • Baltimore, Maryland, États-Unis, 21287
        • Johns Hopkins Hospital
    • Massachusetts
      • Boston, Massachusetts, États-Unis, 02115
        • Boston Children's Hospital
    • Missouri
      • Kansas City, Missouri, États-Unis, 64018
        • Children's Mercy Hospital and Clinics
    • New York
      • New Hyde Park, New York, États-Unis, 11042
        • Northwell Health System
      • New York, New York, États-Unis, 10016
        • Hassenfeld Children's Hospital at NYU Langone
      • New York, New York, États-Unis, 10032
        • New York-Presbyterian / Columbia University Irving Medical Center
      • The Bronx, New York, États-Unis, 10467
        • The Childrens Hospital at Montefiore Albert Einstein School of Medicine
    • North Carolina
      • Durham, North Carolina, États-Unis, 27710
        • Atrium Health Carolinas Medical
    • Ohio
      • Cincinnati, Ohio, États-Unis, 45229
        • Cincinnati Children's Hospital
    • Oregon
      • Portland, Oregon, États-Unis, 97239
        • Oregon Health Science University School of Medicine
    • Tennessee
      • Nashville, Tennessee, États-Unis, 37232
        • Monroe Carell Jr. Childrens Hospital at Vanderbilt
    • Texas
      • Dallas, Texas, États-Unis, 75207
        • Childrens Medical Center of Dallas University of Texas Southwestern
      • Houston, Texas, États-Unis, 77030
        • Texas Children's Hospital
      • San Antonio, Texas, États-Unis, 78215
        • Texas Liver Institute

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Enfant
  • Adulte
  • Adulte plus âgé

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

Cohort 1 :

  1. Completion of the 24-week Treatment Period of Study A4250-012
  2. Signed informed consent and assent as appropriate. Patients who turn 18 years of age (or legal age per country) during the study will be required to re-consent to remain on the study
  3. Caregivers (and age-appropriate patients) must be willing and able to use an electronic diary (eDiary) device as required by the study
  4. Sexually active males and females must agree to use a reliable contraceptive method with ≤1% failure rate (such as hormonal contraception, intra-uterine device, or complete abstinence) from signed informed consent through 90 days after last dose of study drug.

Cohort 2 :

  1. Infant with clinically confirmed ALGS , ≤11 months of age at Study Day 1
  2. Body weight ≥2 kg at Study Day 1
  3. Gestational age ≥36 weeks. For children born with gestational age between 32 and 36 weeks, a postmenstrual age of ≥36 weeks is required .
  4. Signed parent/legal guardian informed consent.

Exclusion Criteria:

Cohort 1 :

  1. Decompensated liver disease, history or presence of clinically significant ascites, variceal hemorrhage, and/or encephalopathy
  2. Patients who were not compliant with study drug treatment or procedures in Study A4250-012
  3. Any other conditions or abnormalities which, in the opinion of the investigator, may compromise the safety of the patient, or interfere with the patient participating in or completing the study
  4. Known hypersensitivity to any components of odevixibat

Cohort 2 :

  1. Patient with past medical history or ongoing presence of other types of liver disease including, but not limited to, the following:

    1. Biliary atresia of any kind
    2. Progressive familial intrahepatic cholestasis (PFIC)
    3. Benign recurrent intrahepatic cholestasis
  2. Patient with a past medical history or ongoing presence of any other disease or condition known to interfere with the absorption, distribution, metabolism (specifically bile acid metabolism), or excretion of drugs in the intestine, including but not limited to, inflammatory bowel disease

  3. Patient with past medical history or ongoing chronic diarrhea requiring intravenous fluid or nutritional intervention for treatment of the diarrhea and/or its sequelae

  4. Patient has a confirmed past diagnosis of infection with human immunodeficiency virus or other present and active, clinically significant chronic infection

  5. Recent infection requiring hospitalization or treatment with parenteral anti-infective within 4 weeks of Study Day 1 or completion of oral anti-infective treatment within 2 weeks prior to the Screening Visit

  6. Cancer diagnosis (except for basal cell carcinoma)

  7. Chronic kidney disease with an impaired renal function and a glomerular filtration rate <70 mL/min/1.73 m2

  8. Patient with surgical history of disruption of the enterohepatic circulation (biliary diversion surgery) within 6 months prior to the Screening Visit

  9. Patient has had a liver transplant, or a liver transplant is planned within 6 months of Study Day 1

  10. Decompensated liver disease, history or presence of clinically significant ascites, variceal hemorrhage, and/or encephalopathy

  11. International normalized ratio (INR) >1.4 (the patient may be treated with Vitamin K, and if INR is ≤1.4 at resampling the patient may be enrolled)

  12. Serum alanine aminotransferase (ALT) >10 × upper limit of normal (ULN) at Screening

  13. Serum ALT >15 × ULN at any time point during the last 6 months unless an alternate etiology was confirmed for the elevation

  14. Total bilirubin >15 × ULN at Screening

  15. Patient suffers from uncontrolled, recalcitrant pruritic condition other than ALGS. Examples include, but not limited to, refractory atopic dermatitis or other primary pruritic skin diseases.

  16. Patient exposed to alcohol or substance abuse in utero

  17. Bile acid or lipid binding resins and medications that slow gastrointestinal motility

  18. Patient has had investigational exposure to a drug, biologic agent, or medical device within 30 days prior to the Screening Visit, or 5 half-lives of the study agent, whichever is longer

  19. Any other conditions or abnormalities which, in the opinion of the investigator may compromise the safety of the patient, or interfere with the patient participating in or completing the study

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Odevixibat (A4250)

Capsules for oral administration once daily for 72 weeks.

Odevixibat is a small molecule and selective inhibitor of IBAT.

Autres noms:
  • A4250

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Changement par rapport à la valeur initiale des médicaments concomitants.
Délai: Base de référence jusqu'à la semaine 12 (cohorte 2).
Base de référence jusqu'à la semaine 12 (cohorte 2).
Changement par rapport à la valeur initiale des niveaux de vitamines liposolubles.
Délai: Base de référence jusqu'à la semaine 12 (cohorte 2).
Base de référence jusqu'à la semaine 12 (cohorte 2).
Change from baseline in pruritus
Délai: Baseline to week 72 (cohort 1).

Assessed as change in scratching score as measured by measured by the Albireo Observer-Reported Outcome Caregiver Instrument.

Baseline to week 72 (cohort 1).
Percentage of participants with Treatment Emergent Adverse Event (TEAEs) and Serious Adverse Events (SAEs)
Délai: Baseline to week 12 (cohort 2).

An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A serious adverse event (SAE) is an AE that results in any of following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent adverse events. TEAEs included both Serious TEAEs and non-serious TEAEs.

Baseline to week 12 (cohort 2).
Percentage of participants with clinically significant changes from baseline in Physical Examination
Délai: Baseline to week 12 (cohort 2).

The clinical significance will be graded by the investigator.

Baseline to week 12 (cohort 2).
Percentage of participants with clinically significant changes in Laboratory Parameters
Délai: Baseline to week 12 (cohort 2).

The following laboratory parameters will be reported: blood chemistry, hematology and coagulation. The clinical significance will be graded by the investigator.

Baseline to week 12 (cohort 2).
Percentage of participants with clinically significant changes from baseline in Vital Signs.
Délai: Baseline to week 12 (cohort 2).

The clinical significance will be graded by the investigator.

Baseline to week 12 (cohort 2).

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Changement par rapport à la valeur initiale des taux sériques d'acides biliaires
Délai: Référence jusqu'à la semaine 72 (cohorte 1).
Référence jusqu'à la semaine 72 (cohorte 1).
Changement par rapport à la valeur initiale des taux sériques d'acides biliaires.
Délai: Référence jusqu'à la semaine 72 (cohorte 1).
Référence jusqu'à la semaine 72 (cohorte 1).
Nombre de participants avec changement par rapport au départ lors de l'examen physique
Délai: Référence jusqu'à la semaine 72 (cohorte 1).
Référence jusqu'à la semaine 72 (cohorte 1).
Nombre de participants présentant un changement par rapport à la valeur initiale des signes vitaux
Délai: Référence jusqu'à la semaine 72 (cohorte 1).
Référence jusqu'à la semaine 72 (cohorte 1).
Changement par rapport à la valeur initiale des médicaments concomitants
Délai: Référence jusqu'à la semaine 72 (cohorte 1).
Référence jusqu'à la semaine 72 (cohorte 1).
Changement par rapport à la valeur initiale des résultats des tests de laboratoire Cmax pharmacocinétique (PK) [Délai : jour 1, semaine 4, semaine 8 et semaine 12]
Délai: Référence jusqu'à la semaine 72 (cohorte 1).
Référence jusqu'à la semaine 72 (cohorte 1).
Changement par rapport à la valeur initiale de la concentration plasmatique du médicament à l'étude
Délai: Jour 1, semaine 4, semaine 8 et semaine 12 (cohorte 1).
Jour 1, semaine 4, semaine 8 et semaine 12 (cohorte 1).
Paramètres pharmacodynamiques : modification des taux sériques d'acides biliaires
Délai: Référence jusqu'à la semaine 12 (cohorte 2).
Référence jusqu'à la semaine 12 (cohorte 2).
Change from baseline in patient reported and observer reported itching and scratching severity scores
Délai: Baseline to week 72 (cohort 1).

Assessed by the the Albireo ObsRO/ Patient Reported Outcomes (PRO) instruments. The Albireo ObsRO/PRO scratching and itch severity items use 0 to 4 response scales, where each response is distinguished by a unique facial expression, verbal anchor, number, and color code.

Baseline to week 72 (cohort 1).
Percentage of participants achieving a clinically meaningful decrease in pruritus (pruritus responders)
Délai: Baseline to week 72 (cohort 1).

Assessed by the Albireo ObsRO/patient reported outcomes (PRO) instruments

Baseline to week 72 (cohort 1).
Change from baseline in sleep parameters.
Délai: Baseline to week 72 (cohort 1).

Assessed with the Albireo ObsRO/PRO instruments (e.g: tiredness and number of awakenings).

Baseline to week 72 (cohort 1).
Change from baseline in Pediatric Quality of Life Inventory (PedsQL) scores.
Délai: Baseline to week 72 (cohort 1).

The PedsQL instrument consists of 36 questions and uses a 5-point response scales, where higher scores indicates worst symptoms.

Baseline to week 72 (cohort 1).
Change from baseline in in Global Symptom Relief: Patient Global Impression of Improvement (PGIC) score.
Délai: Baseline to Weeks 4, 12, 24, 48 and 72 (cohort 1).

The Patient Global Impression of Change (PGIC) is a patient-reported instrument that measures change in overall status on a scale ranging from one ("very much improved") to seven ("very much worse").

Baseline to Weeks 4, 12, 24, 48 and 72 (cohort 1).
Change from baseline in in Global Symptom Relief: Clinical Global Impression of Improvement (CGIC) score.
Délai: Baseline to Weeks 4, 12, 24, 48 and 72 (cohort 1).

The Clinical Global Impression of Change (CGIC) is a clinician-reported instrument that measures change in overall status on a scale ranging from one ("very much improved") to seven ("very much worse").

Baseline to Weeks 4, 12, 24, 48 and 72 (cohort 1).
Change from baseline in in Global Symptom Relief: Caregiver Global Impression of Change (CaGIC) score
Délai: Baseline to Weeks 4, 12, 24, 48 and 72 (cohort 1).

The caregiver Global Impression of Change is a caregiver-reported instrument that measures change in overall status on a scale ranging from one ("very much improved") to seven ("very much worse").

Baseline to Weeks 4, 12, 24, 48 and 72 (cohort 1).
Percentage of participants with Treatment Emergent Adverse Event (TEAEs) and Serious Adverse Events (SAEs)
Délai: Baseline to week 72 (cohort 1).

An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A serious adverse event (SAE) is an AE that resultes in any of following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent adverse events. TEAEs included both Serious TEAEs and non-serious TEAEs.

Baseline to week 72 (cohort 1).

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Directeur d'études: Ipsen Medical Director, Ipsen

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

3 septembre 2021

Achèvement primaire (Estimé)

15 février 2027

Achèvement de l'étude (Estimé)

15 février 2027

Dates d'inscription aux études

Première soumission

13 août 2021

Première soumission répondant aux critères de contrôle qualité

1 septembre 2021

Première publication (Réel)

5 septembre 2021

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

23 octobre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

20 octobre 2026

Dernière vérification

1 octobre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications.

Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.

Délai de partage IPD

Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.

Critères d'accès au partage IPD

Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner